Pleural effusion is a negative prognostic factor for immunotherapy in patients with non-small cell lung cancer (NSCLC): The pluie study

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

Bertrand Routy, Emmanuelle Le Chatelier, Lisa Derosa et al. · Science · 2017 · 5.4K citations

Life Sciences, Immunology, Oncology +17

Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer

Laura Mezquita, Édouard Auclin, Roberto Ferrara et al. · JAMA Oncology · 2018 · 951 citations · Full text

Life Sciences, Immunology, Oncology +17

Malignant effusions and immunogenic tumour-derived exosomes

Fabrice André, Noël E.C. Schartz, Mojgan Movassagh et al. · The Lancet · 2002 · 940 citations

Life Sciences, Immunology, Oncology +14

Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010

Mark Roberts, E Neville, Richard Berrisford et al. · Thorax · 2010 · 888 citations · Full text

Medicine, Oncology, Pulmonology +9